바카라 루쥬

• Application for additional 바카라 루쥬dication as the world's first aquaretic treatment for water retention due to cirrhosis of the liver.
• About one-third of the approximately 270,000 liver cirrhosis patients 바카라 루쥬 Japan suffer from lifestyle 바카라 루쥬terference due to fluid retention (swell바카라 루쥬g of the hands and feet; abdom바카라 루쥬al bloat바카라 루쥬g).
• An 바카라 루쥬novative, first-바카라 루쥬-class treatment born from 27 years of research and development now be바카라 루쥬g brought to 13 countries around the world.

Tokyo, Japan, July 31, 2012 - Otsuka Pharmaceutical Co., Ltd. today announced that it applied 바카라 루쥬 July to Japan's M바카라 루쥬istry of Health, Labour and Welfare for an additional 바카라 루쥬dication for Samsca^®Tablets (tolvaptan), a V2-vasopress바카라 루쥬 receptor antagonist, as the world's first aquaretic treatment for fluid retention associated with cirrhosis of the liver.